New cytostatics--more activity and less toxicity.
Berger
M R
MR
Institute of Toxicology and Chemotherapy, German Cancer Research Center, Heidelberg.
Richter
H
H
Seelig
M H
MH
Eibl
H
H
Schmähl
D
D
D000230:Adenocarcinoma / Q000188:drug therapy; D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy; D005260:Female; D008297:Male; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy; D010052:Ovariectomy; D010655:Phenylenediamines / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*; D010767:Phosphorylcholine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000737:chemistry / Q000627:therapeutic use; D051381:Rats; D011919:Rats, Inbred Strains; D012074:Remission Induction; D013329:Structure-Activity Relationship
D000970:Antineoplastic Agents; D010655:Phenylenediamines; D010767:Phosphorylcholine; C039128:miltefosine; C045838:dinaline